CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Diamedica Therapeutics INC. (DMAC) / recombinant human tissue kallikrein
Forward catalyst · DMAC

recombinant human tissue kallikrein

Sponsor Diamedica Therapeutics INC. · listed as DMAC

READOUT Phase 2/3 Confidence: medium Source: clinicaltrials

recombinant human tissue kallikrein is a drug asset sponsored by Diamedica Therapeutics INC., listed as DMAC. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 2026 (month precision, medium confidence), tied to trial NCT05065216. That trial is in Phase 2/3 and currently recruiting, studying Acute Stroke.

Next catalyst

Event typeREADOUT
Expected date2026-12-31
As disclosedDec 2026
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05065216
PhasePHASE2;PHASE3
StatusRECRUITING
Lead sponsorDiaMedica Therapeutics Inc
Listed asDMAC
Condition(s)Acute Stroke; Ischemic Stroke; Stroke
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.

Get the full dataset — $499 →   More DMAC catalysts

Related catalysts and sponsor